Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Impact · against what's priced in

Lyell Immunopharma's updated data provides positive validation of the safety and manufacturing reliability of ronde-cel, alongside a concrete regulatory timeline for a 2027 BLA submission. The lack of high-grade CRS and the 97% manufacturing success rate significantly derisk the path to commercialization.

LYEL+0.60: No priced-in read yet

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

What matters in this story

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

What matters in this story

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

How each ticker is affected

Track these names every morning.

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

Almirall 9M 2026 Results

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

What matters in this story

Next reads from the same story arc

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

What matters in this story

Next reads from the same story arc

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

How each ticker is affected

Track these names every morning.

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

Almirall 9M 2026 Results

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines